Saxenda vs Wegovy: Liraglutide vs Semaglutide, Compared Head-to-Head

Before semaglutide, there was liraglutide. Saxenda was the FDA-approved GLP-1 standard for chronic weight management for years before Wegovy existed, and it is still prescribed today — but the two are no longer close on either dosing burden or average results, and a direct trial measured exactly how far apart.

Daily injections vs weekly — a real day-to-day difference

Per Saxenda's FDA prescribing information, liraglutide is injected subcutaneously once daily, at any time of day, starting at 0.6 mg and increasing in weekly steps to a maintenance dose of 3 mg daily¹ — reaching maximum dose in about 5 weeks. Wegovy is injected once weekly, starting at 0.25 mg and stepping up every 4 weeks to a standard maintenance dose of 2.4 mg, with a labeled ceiling of 7.2 mg for added weight loss in patients who've tolerated 2.4 mg² — see the full titration schedule for the exact week-by-week breakdown. That is a genuinely different day-to-day commitment: 365 injections a year on Saxenda versus 52 on Wegovy, which is one reason semaglutide displaced liraglutide as quickly as it did once it reached the market, independent of the efficacy question below.

The pivotal trials, then the head-to-head

Liraglutide's own pivotal trial, the SCALE program, established Saxenda's efficacy against placebo in 2015¹³ and remains the FDA-cited evidence behind its approval. Semaglutide's STEP 1 trial, nearly a decade later, reported roughly 15% mean weight loss over 68 weeks⁴ — well above liraglutide's pivotal-trial results. But the number that actually settles the comparison is STEP 8, a randomized trial that put weekly semaglutide 2.4 mg directly against daily liraglutide 3 mg in the same patients under the same conditions: semaglutide produced significantly greater weight loss than liraglutide, with a similar overall gastrointestinal side-effect profile between the two⁵. That is a direct, apples-to-apples answer, not an inference across two separate placebo-controlled trials run years apart.

Why Saxenda still has a place

None of this makes liraglutide obsolete. It has the longest real-world track record of any GLP-1 used for weight management, a well-characterized safety profile from a decade of use, and it remains an FDA-approved option for patients who don't tolerate semaglutide or tirzepatide, or whose insurance plan specifically covers it when the newer molecules are excluded. See semaglutide side effects for what the newer molecule's trial data reports, for comparison.

The cost picture — and one honest gap

Wegovy's manufacturer self-pay price runs around $499/month through Novo Nordisk's direct channel (see the full cash-pay breakdown). Saxenda is available brand-name through several of the same telehealth platforms that carry Wegovy and Zepbound, but none of the providers in our verified roster discloses a standalone Saxenda cash price we can cite with confidence — so rather than repeat an unverified number, the honest answer is: ask any brand-access provider for Saxenda's current self-pay or savings-card price directly and compare it against Wegovy's disclosed figure before assuming either is cheaper.

How to decide

If average weight loss is your main criterion and you can tolerate a weekly injection, STEP 8's head-to-head result favors Wegovy. If you're already stable on liraglutide, have a specific reason to avoid semaglutide, or your coverage is built around Saxenda specifically, its FDA-approved status and long track record remain real advantages worth keeping rather than switching on a percentage alone. Either way, verify your actual monthly and annual cost — brand or compounded — using our cost calculators before you decide. The trials behind this comparison are indexed in our research library. Not medical advice — see our medical disclaimer and talk to a clinician about which molecule fits your history.